Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Revenue (2021 - 2024)

Solid Biosciences' Revenue history spans 4 years, with the latest figure at -$75000.0 for Q4 2024.

  • For Q4 2024, Revenue changed N/A year-over-year to -$75000.0; the TTM value through Dec 2024 reached -$340000.0, down 46.55%, while the annual FY2024 figure was -$340000.0, N/A changed from the prior year.
  • Revenue for Q4 2024 was -$75000.0 at Solid Biosciences, up from -$82000.0 in the prior quarter.
  • Across five years, Revenue topped out at $6.2 million in Q2 2022 and bottomed at -$8.1 million in Q4 2022.
  • The 4-year median for Revenue is -$78500.0 (2024), against an average of $824500.0.
  • The largest annual shift saw Revenue surged 71.65% in 2022 before it tumbled 106.29% in 2023.
  • A 4-year view of Revenue shows it stood at $3.5 million in 2021, then crashed by 328.84% to -$8.1 million in 2022, then surged by 98.63% to -$111000.0 in 2023, then skyrocketed by 32.43% to -$75000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Revenue are -$75000.0 (Q4 2024), -$82000.0 (Q3 2024), and -$88000.0 (Q2 2024).